Berger Montague Securities Fraud Investigation: APYX MEDICAL CORPORATION – Apyx Medical Corp. (NASDAQ: APYX); Lead Plaintiff Deadline is August 5, 2022

PHILADELPHIA, July 20, 2022 /PRNewswire/ — Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) between May 12, 2021 and March 11, 2022 (the “Class Period”).

Berger Montague Securities Fraud Investigation: APYX MEDICAL CORPORATION – Apyx Medical Corp. 

If you purchased the securities of Apyx during the Class Period, would like to discuss Berger Montague’s investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at [email protected] or (215) 875-3015, or Michael Dell‘Angelo at [email protected] or (215) 875-3080 or visit: 

On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Company’s Advanced Energy Products. The Company further disclosed that “[b]ased on our initial interactions with the FDA, we believe the Agency’s MDSC will pertain to the use of our Advanced Energy

products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures.”

On this news, Apyx’s stock fell $4.02, or 40.6%, to close at $5.88 per share on March 14, 2022, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants misled investors about the fact that: (1) a significant number of Apyx’s Advanced Energy products were used for off-label indications; and (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events.

Whistleblowers: Anyone with non-public information regarding Apyx is encouraged to confidentially assist Berger Montague’s investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected] 

Michael Dell‘Angelo, Executive Shareholder
Berger Montague
(215) 875-3080
[email protected] 

Cision View original content to download multimedia:—apyx-medical-corp-nasdaq-apyx-lead-plaintiff-deadline-is-august-5-2022-301590391.html

SOURCE Berger Montague

Berger Montague Securities Fraud Investigation: APYX MEDICAL CORPORATION - Apyx Medical Corp. (NASDAQ: APYX); Lead Plaintiff Deadline is August 5, 2022 WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

World Reviewer Staff
World Reviewer Staff
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles